High Potency Active Pharmaceutical Ingredients (HPAPI)-Europe Market Status and Trend Report 2013-2023
SKU ID :MI-12207620 | Published Date: 08-May-2018 | No. of pages: 136Description
TOC
Table of Contents
Chapter 1 Overview of High Potency Active Pharmaceutical Ingredients (HPAPI)
1.1 Definition of High Potency Active Pharmaceutical Ingredients (HPAPI) in This Report
1.2 Commercial Types of High Potency Active Pharmaceutical Ingredients (HPAPI)
1.2.1 Synthetic
1.2.2 Biotech
1.3 Downstream Application of High Potency Active Pharmaceutical Ingredients (HPAPI)
1.3.1 Synthetic
1.3.2 Biotech Oncology
1.3.3 Hormonal
1.3.4 Glaucoma
1.3.5 Others
1.4 Development History of High Potency Active Pharmaceutical Ingredients (HPAPI)
1.5 Market Status and Trend of High Potency Active Pharmaceutical Ingredients (HPAPI) 2013-2023
1.5.1 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023
1.5.2 Regional High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023
Chapter 2 Europe Market Status and Forecast by Regions
2.1 Market Status of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe 2013-2017
2.2 Consumption Market of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions
2.2.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions
2.2.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions
2.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions
2.3.1 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Germany 2013-2017
2.3.2 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in United Kingdom 2013-2017
2.3.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in France 2013-2017
2.3.4 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Italy 2013-2017
2.3.5 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Spain 2013-2017
2.3.6 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Benelux 2013-2017
2.3.7 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Russia 2013-2017
2.4 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe 2018-2023
2.4.1 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe 2018-2023
2.4.2 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) by Regions 2018-2023
Chapter 3 Europe Market Status and Forecast by Types
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Types
3.1.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Types
Chapter 4 Europe Market Status and Forecast by Downstream Industry
4.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Downstream Industry
4.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Major Countries
4.2.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Germany
4.2.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in United Kingdom
4.2.3 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in France
4.2.4 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Italy
4.2.5 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Spain
4.2.6 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Benelux
4.2.7 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Russia
4.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Downstream Industry
Chapter 5 Market Driving Factor Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
5.1 Europe Economy Situation and Trend Overview
5.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Downstream Industry Situation and Trend Overview
Chapter 6 High Potency Active Pharmaceutical Ingredients (HPAPI) Market Competition Status by Major Players in Europe
6.1 Sales Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Major Players
6.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Major Players
6.3 Basic Information of High Potency Active Pharmaceutical Ingredients (HPAPI) by Major Players
6.3.1 Headquarters Location and Established Time of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players
6.3.2 Employees and Revenue Level of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
Chapter 7 High Potency Active Pharmaceutical Ingredients (HPAPI) Major Manufacturers Introduction and Market Data
7.1 Eli Lilly and Company
7.1.1 Company profile
7.1.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.1.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.2 Novartis International AG
7.2.1 Company profile
7.2.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.2.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Novartis International AG
7.3 Bristol-Myers Squibb Company
7.3.1 Company profile
7.3.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.3.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company
7.4 Roche Diagnostics Limited
7.4.1 Company profile
7.4.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.4.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Roche Diagnostics Limited
7.5 Sanofi Aventis
7.5.1 Company profile
7.5.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.5.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sanofi Aventis
7.6 Hospira, Inc.
7.6.1 Company profile
7.6.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.6.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Hospira, Inc.
7.7 BASF AG
7.7.1 Company profile
7.7.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.7.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of BASF AG
7.8 Covidien Plc
7.8.1 Company profile
7.8.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.8.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Covidien Plc
7.9 Boehringer Ingelheim GmbH
7.9.1 Company profile
7.9.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.9.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
7.10 Merck & Co., Inc.
7.10.1 Company profile
7.10.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.10.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.11 Sigma Aldrich Corporation
7.11.1 Company profile
7.11.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.11.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sigma Aldrich Corporation
7.12 Bayer AG
7.12.1 Company profile
7.12.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.12.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bayer AG
7.13 Carbogen Amcis AG
7.13.1 Company profile
7.13.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.13.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Carbogen Amcis AG
7.14 Lonza
7.14.1 Company profile
7.14.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.14.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Lonza
7.15 Teva Pharmaceuticals Industries Ltd.
7.15.1 Company profile
7.15.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product
7.15.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals Industries Ltd.
Chapter 8 Upstream and Downstream Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
8.1 Industry Chain of High Potency Active Pharmaceutical Ingredients (HPAPI)
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
9.1 Cost Structure Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
9.2 Raw Materials Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
9.3 Labor Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
9.4 Manufacturing Expenses Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
Chapter 10 Marketing Status Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
Tables & Figures
List of Tables
Table Advantage and Disadvantage of Synthetic
Table Advantage and Disadvantage of Biotech
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions 2013-2017
Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions 2018-2023
Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Regions 2018-2023
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Types 2013-2017
Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Types 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Germany 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in United Kingdom 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in France 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Italy 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Spain 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Benelux 2013-2017
Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Russia 2013-2017
Table Consumption Volume Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Types 2018-2023
Table Revenue Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Types 2018-2023
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Downstream Industry 2013-2017
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Germany 2013-2017
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in United Kingdom 2013-2017
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in France 2013-2017
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Italy 2013-2017
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Spain 2013-2017
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Benelux 2013-2017
Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Russia 2013-2017
Table Demand Volume Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Downstream Industry 2018-2023
Table Sales Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Major Players 2013-2017
Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe by Major Players 2013-2017
Table Headquarters Location and Established Time of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players
Table Employees and Revenue Level of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Eli Lilly and Company
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Eli Lilly and Company
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Eli Lilly and Company 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Novartis International AG
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Novartis International AG
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Novartis International AG 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Bristol-Myers Squibb Company
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Bristol-Myers Squibb Company
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Roche Diagnostics Limited
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Roche Diagnostics Limited
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Roche Diagnostics Limited 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Sanofi Aventis
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Sanofi Aventis
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sanofi Aventis 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Hospira, Inc.
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Hospira, Inc.
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Hospira, Inc. 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of BASF AG
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of BASF AG
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of BASF AG 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Covidien Plc
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Covidien Plc
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Covidien Plc 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Boehringer Ingelheim GmbH
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Boehringer Ingelheim GmbH
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Merck & Co., Inc.
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Merck & Co., Inc.
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Sigma Aldrich Corporation
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Sigma Aldrich Corporation
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sigma Aldrich Corporation 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Bayer AG
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Bayer AG
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bayer AG 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Carbogen Amcis AG
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Carbogen Amcis AG
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Carbogen Amcis AG 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Lonza
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Lonza
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Lonza 2013-2017
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Teva Pharmaceuticals Industries Ltd.
Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Teva Pharmaceuticals Industries Ltd.
Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals Industries Ltd. 2013-2017
Companies
- PRICE
-
$3480$5980